CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The company is currently focused on the clinical development of aldoxorubicin, modified version of a chemotherapeutic agent, doxorubicin, and recently reported results of Phase 2b clinical trial with aldoxorubicin. Aldoxorubicin, formlerly INNO-206 is a tumor-targeted doxorubicin conjugate. Aldoxorubicin has been granted orphan drug designation by the Office of Orphan Product Development of the U.S. Food and Drug Administration (FDA) for the treatment of patients with soft tissue sarcomas and pancreatic cancer. CytRx has initiated a Phase III pivotal trial. The Company’s key products are: Aldoxorubicin, Bafetinib and Tamibarotene.